ERBB2 (D769H)
Sign in to save this workspaceERBB2 · Variant type: point · HGVS: p.D769H
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Osimertinib | 100.0% | 0.0% | 97.24 |
| 2 | Canertinib | 99.7% | 0.3% | 96.49 |
| 3 | Mobocertinib | 99.5% | 0.5% | 97.22 |
| 4 | Afatinib | 99.4% | 0.6% | 98.50 |
| 5 | Dacomitinib | 99.0% | 1.0% | 97.99 |
| 6 | Neratinib | 98.9% | 1.1% | 93.18 |
| 7 | Lazertinib | 96.8% | 3.3% | 97.47 |
| 8 | Lapatinib | 95.1% | 4.9% | 99.25 |
| 9 | Pralsetinib | 94.8% | 5.2% | 93.43 |
| 10 | Erlotinib | 93.8% | 6.2% | 99.75 |
| 11 | Brigatinib | 92.8% | 7.2% | 82.96 |
| 12 | Ibrutinib | 92.8% | 7.2% | 94.74 |
| 13 | Darovasertib | 91.3% | 8.7% | 96.99 |
| 14 | Gefitinib | 91.3% | 8.7% | 99.25 |
| 15 | Avapritinib | 90.2% | 9.8% | 97.73 |
| 16 | Vandetanib | 87.7% | 12.3% | 95.74 |
| 17 | Bosutinib | 87.1% | 12.9% | 87.22 |
| 18 | Fostamatinib | 81.0% | 19.0% | 96.74 |
| 19 | Ponatinib | 73.5% | 26.5% | 78.23 |
| 20 | Dasatinib | 59.0% | 41.0% | 87.97 |
| 21 | Alectinib | 46.1% | 53.9% | 95.49 |
| 22 | Pacritinib | 37.2% | 62.8% | 88.64 |
| 23 | Zanubrutinib | 35.2% | 64.8% | 98.24 |
| 24 | Nintedanib | 30.5% | 69.5% | 90.23 |
| 25 | Alpelisib | 27.9% | 72.1% | 97.22 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Osimertinib | 100.0% | — | — |
| Canertinib | 99.7% | — | — |
| Mobocertinib | 99.5% | — | — |
| Afatinib | 99.4% | — | — |
| Dacomitinib | 99.0% | — | — |
| Neratinib | 98.9% | — | — |
| Lazertinib | 96.8% | — | — |
| Lapatinib | 95.1% | — | — |
| Pralsetinib | 94.8% | — | — |
| Erlotinib | 93.8% | — | — |
| Brigatinib | 92.8% | — | — |
| Ibrutinib | 92.8% | — | — |
| Darovasertib | 91.3% | — | — |
| Gefitinib | 91.3% | — | — |
| Avapritinib | 90.2% | — | — |
| Vandetanib | 87.7% | — | — |
| Bosutinib | 87.1% | — | — |
| Fostamatinib | 81.0% | — | — |
| Ponatinib | 73.5% | — | — |
| Dasatinib | 59.0% | — | — |
| Alectinib | 46.1% | — | — |
| Pacritinib | 37.2% | — | — |
| Zanubrutinib | 35.2% | — | — |
| Nintedanib | 30.5% | — | — |
| Alpelisib | 27.9% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_breast | Breast | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.9ms